Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 11/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.35 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.35 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23668146 | 1.00 | TSHR (0.41) | TSHRP2RY12FAAHNTRK1KCNJ6 | |
| SCHEMBL21808191 | 1.00 | TSHR (0.41) | TSHRP2RY12FAAHNTRK1KCNJ6 | |
| SCHEMBL21808190 | 1.00 | TSHR (0.41) | TSHRP2RY12FAAHNTRK1KCNJ6 | |
| SCHEMBL23668148 | 1.00 | TSHR (0.41) | TSHRP2RY12FAAHNTRK1KCNJ6 | |
| SCHEMBL21808189 | 1.00 | TSHR (0.41) | TSHRP2RY12FAAHNTRK1KCNJ6 | |
| Hydrochloric Acid SCHEMBL23668155 | 0.99 | TSHR (0.40) | TSHRP2RY12FAAHNTRK1KCNJ6 | |
| Hydrochloric Acid SCHEMBL23668128 | 0.99 | TSHR (0.40) | TSHRP2RY12FAAHNTRK1KCNJ6 | |
| Hydrochloric Acid SCHEMBL23668127 | 0.99 | TSHR (0.40) | TSHRP2RY12FAAHNTRK1KCNJ6 | |
| Hydrochloric Acid SCHEMBL23668126 | 0.99 | TSHR (0.40) | TSHRP2RY12FAAHNTRK1KCNJ6 | |
| Hydrochloric Acid SCHEMBL23668154 | 0.99 | TSHR (0.40) | TSHRP2RY12FAAHNTRK1KCNJ6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427547-B2 | Edaravone prodrug compound and pharmaceutical use thereof in treatment or alleviation of neurodegenerative or motor neuron disease | J2H BIOTECH INC. (KR) | 2022-08-30 | — | — | US | claimed |
| US-20220033359-A1 | EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE | Theragen Etex Co., Ltd (KR) | 2022-02-03 | — | — | US | claimed |
| EP-3854787-A1 | EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE | J2H Biotech Inc. (KR) | 2021-07-28 | — | — | EP | claimed |
| CN-112714760-A | Edaravone prodrug compound and medical application thereof in treating or improving neurodegenerative or motor neuron diseases | J2H生物科技有限公司 | 2021-04-27 | — | — | CN | claimed |
| US-11427547-B2 | Edaravone prodrug compound and pharmaceutical use thereof in treatment or alleviation of neurodegenerative or motor neuron disease | J2H BIOTECH INC. (KR) | 2022-08-30 | — | — | US | disclosed |
| US-20220033359-A1 | EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE | Theragen Etex Co., Ltd (KR) | 2022-02-03 | — | — | US | disclosed |
| US-20220033359-A1 | EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE | Theragen Etex Co., Ltd (KR) | 2022-02-03 | — | — | US | disclosed |
| EP-3854787-A1 | EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE | J2H Biotech Inc. (KR) | 2021-07-28 | — | — | EP | disclosed |
| CN-112714760-A | Edaravone prodrug compound and medical application thereof in treating or improving neurodegenerative or motor neuron diseases | J2H生物科技有限公司 | 2021-04-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427547-B2 | Edaravone prodrug compound and pharmaceutical use thereof in treatment or alleviation of neurodegenerative or motor neuron disease | SMN1; SMN2, NLN, EDNRA | TSHR 4538/4885P2RY12 1560/4885FAAH 2983/4885 |
| US-20220033359-A1 | EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE | SMN1; SMN2, NLN, EDNRA | TSHR 4538/4885P2RY12 1560/4885FAAH 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.